Bank of Nova Scotia
AZN icon

Bank of Nova Scotia’s AstraZeneca AZN Stock Holding History

Bank of Nova Scotia’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,195
Closed -$771K – 1087
2025
Q4 		$771K Buy
4,195
+217
+5% +$38.1K ﹤0.01% 915
2025
Q3 		$610K Buy
3,978
+1,365
+52% +$207K ﹤0.01% 861
2025
Q2 		$365K Sell
2,613
-1,080
-29% -$151K ﹤0.01% 908
2025
Q1 		$543K Buy
3,693
+1,312
+55% +$190K ﹤0.01% 808
2024
Q4 		$312K Buy
+2,381
New +$333K ﹤0.01% 921
2023
Q1 		– Sell
-1,663
Closed -$226K – 1134
2022
Q4 		$226K Sell
1,663
-770
-32% -$96.6K ﹤0.01% 1091
2022
Q3 		$267K Sell
2,433
-248
-9% -$31.5K ﹤0.01% 1056
2022
Q2 		$355K Buy
+2,681
New +$352K ﹤0.01% 1061

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Bank of Nova Scotia's AZN Position: Q1 2026 in Review

Bank of Nova Scotia sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 4,195 shares — an estimated $771K sold.

Bank of Nova Scotia first reported a position in AZN in Q2 2022 and held it in 8 quarters. The position peaked at $771K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Bank of Nova Scotia reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Bank of Nova Scotia sold 4,195 AstraZeneca shares in Q1 2026, an estimated $771K.
  • Bank of Nova Scotia first reported a position in AstraZeneca in Q2 2022 and held it in 8 quarters.
  • Bank of Nova Scotia's AstraZeneca position peaked at $771K in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.